A previous report suggested a potential anti-tumor role of DPP-4 inhibition in improvement of tumor immunity by regulating CXCL10-mediated lymphocyte trafficking in mice (5), whereas our recent finding revealed an oncogenic role of DPP-4i in human cancers including BC through NRF2-mediated anti-oxidative stress (6). Here, DPP4 is linked to neoplasm.